A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.. Time-dependent changes in matrix metalloprote
Trang 1collagen content Am J Surg 2000;180(6):498–501
[discussion: 501–2]
[105] Mital S, Loke KE, Addonizio LJ, et al Left
ven-tricular assist device implantation augments nitric
oxide dependent control of mitochondrial
respira-tion in failing human hearts J Am Coll Cardiol
2000;36(6):1897–902
[106] Torre-Amione G, Stetson SJ, Youker KA, et al
De-creased expression of tumor necrosis factor-alpha in
failing human myocardium after mechanical
circu-latory support: a potential mechanism for cardiac
recovery Circulation 1999;100(11):1189–93
[107] Loebe M, Gorman K, Burger R, et al Complement
activation in patients undergoing mechanical
circu-latory support ASAIO J 1998;44(5):M340–6
[108] Dipla K, Mattiello JA, Jeevanandam V, et al
Myo-cyte recovery after mechanical circulatory support
in humans with end-stage heart failure Circulation
1998;97(23):2316–22
[109] McCarthy PM, Nakatani S, Vargo R, et al
Struc-tural and left ventricular histologic changes after
implantable LVAD insertion Ann Thorac Surg
1995;59(3):609–13
[110] Birks EJ, Latif N, Bowles C Measurement of
cyto-kine levels and activation of the apoptotic pathway
in patients requiring left ventricular assist device
(LVAD): implication for timing of implantation
Circulation 1999;99:2565–70
[111] Dec GW, Fuster V Idiopathic dilated
cardio-myopathy N Engl J Med 1994;331:1564–75
[112] Kopecky SL, Gersh BJ Dilated cardiomyopathy
and myocarditis: natural history, etiology, clinical
manifestations, and management Curr Probl
Car-diol 1987;12:573–647
[113] Pauschinger M, Chandrasekharan K, Li J, et al
Mechanisms of extracellular matrix remodeling in
dilated cardiomyopathy Herz 2002;27:677–82
[114] Maisch B Ventricular remodeling Cardiology
1996;87(Suppl 1):2–10
[115] Maisch B Extracellular matrix and cardiac
intersti-tium: restriction is not a restricted phenomenon
Herz 1995;20:75–80
[116] Frank JS, Langer GA The myocardial
interstiti-um: its structure and its role in ionic exchange
J Cell Biol 1974;60:586–601
[117] Weber KT, Janicki JS, Shroff SG, et al Collagen
remodeling of the pressure-overload,
hypertro-phied non-human primate myocardium Circ Res
1988;62:757–65
[118] Li J, Schwimmbeck PL, Tschope C, et al Collagen
degradation in a murine myocarditis model: relevance
of matrix metalloproteinase in association with
inflam-matory induction Cardiovasc Res 2002;56:235–47
[119] Spinale FG, Coker ML, Heung LJ, et al A matrix
metalloproteinase induction/activation system
exists in the human left ventricular myocardium
and is upregulated in heart failure Circulation
2000;102:1944–9
Remodeling of human myocardial collagen in idio-pathic dilated cardiomyopathy: role of metallopro-teinases and pyridinoline cross links Am J Pathol 1996;148:1639–48
[121] Spinale FG, Coker ML, Thomas CV, et al Time-dependent changes in matrix metalloproteinase ac-tivity and expression during the progression of con-gestive heart failure: relation to ventricular and myocyte function Circ Res 1998;82:482–95 [122] Spinale FG, Coker ML, Krombach RS, et al Ma-trix metalloproteinase inhibition during developing congestive heart failure: effects on left ventricular geometry and function Circ Res 1999;85:364–76 [123] Ries C, Petrides PE Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunc-tion in disease Biol Chem 1995;376:345–55 [124] Chancey AL, Brower GL, Peterson JT, et al Effects
of matrix metalloproteinase inhibition on ventricu-lar remodeling due to volume overload Circulation 2002;105:1983–8
[125] Thomas CV, Coker ML, Zellner JL, et al Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy Circula-tion 1998;97:1708–15
[126] Diez J, Laviades C, Mayor G, et al Increased serum concentration of procollagen peptides in essential hypertension Relation to cardiac alter-ation Circulation 1995;91:1450–6
[127] Querejeta R, Varo N, Lopez B, et al Serum carboxy-terminal propeptide of procollagen type I
is a marker of myocardial fibrosis in hypertensive heart disease Circulation 2000;101:1729–35 [128] Poulsen SH, Høst NB, Jensen SE, et al Relation-ship between serum amino-terminal propeptide of type III procollagen and changes of left ventricular function after acute myocardial infarction Circula-tion 2000;101:1527–32
[129] Jensen LT, H-Petersen K, Toft P, et al Serum aminoterminal type III procollagen peptide reflects repair after acute myocardial infarction Circula-tion 1990;81:52–7
[130] Høst NB, Jensen LT, Bendixen PM, et al The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction Am J Cardiol 1995; 76:869–73
[131] Sato Y, Kataoka K, Matsumori A, et al Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac tropo-nin T in patients with idiopathic dilated cardiomy-opathy and secondary cardiomycardiomy-opathy Heart 1997;78:505–8
[132] Klappacher G, Franzen P, Haab D, et al Measur-ing extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardio-myopathy and impact on diagnosis and prognosis
Am J Cardiol 1995;75:913–8
Trang 2Patients Who Have Dilated Cardiomyopathy
Must Have a Trial of Bridge to Recovery:
The Case Against That Proposition
Philip A Poole-Wilson, MD, FRCP, FMedSci * National Heart & Lung Institute, Imperial College London, London, UK
Propositions containing the word ‘‘must’’ are
usually mistaken and this proposition is no
exception.
In the last few years the management of patients
who have severe heart failure has increased in
complexity, requiring greater skills and finer
judg-ment from the physician and surgeon New drugs
have emerged, the expertise of physicians in using
these drugs has improved, the indications for
cardiac transplantation have changed, new surgical
techniques have developed, and effective left
ven-tricular assist devices (LVADs) have become
avail-able The newer LVADs are an engineering
triumph but raise critical issues regarding how
and when they should be used This problem has
been exacerbated by the decline in the number of
patients undergoing transplantation, by the dearth
of donor hearts, and possibly by a growing public
aversion to cardiac transplantation.
Indications for the use of left ventricular
assist devices
The availability on the market of many devices
to assist the pumping function of the heart has
resulted in a new vocabulary This has led to
a surplus of confusion, even misunderstanding,
extending from the characteristics and phenotypes
of patients and the indications for the use of
LVADs to the appropriate assessment of benefit,
if any.
The phrase ‘‘bridge to recovery’’ is used to encapsulate the idea that doctors can identify patients who have reversible cardiac dysfunction and who only require transient support of the circulation before spontaneous functional recov-ery of the heart in situ Established clinical entities
in which this can occur include acute myocarditis, Takotsubo syndrome, acute alcohol ingestion, and depression of cardiac function by toxins or drugs The phrase might also include patients who have cardiogenic shock attributable to a second group
of patients who have myocardial infarction in whom the likely outcome may be transformed In recent years several authors have possibly identi-fied a third group in which a sizable proportion of patients presenting with severe heart failure of idiopathic origin and with large hearts (dilated cardiomyopathy) do recover spontaneously These authors have argued that such patients should receive a device pending a decision as to whether to proceed to transplantation The extent
to which this claim is correct is unknown largely because many of these patients may in reality belong to the other two groups of patients The phrases ‘‘destination treatment’’ or ‘‘life-time therapy’’ are used to describe the intention at the moment of insertion of the device: that it should remain in place for the life of the patient and that there is no intention to proceed to transplantation The first such device inserted with this intention was reported in 2000 [1] Since then many patients around the world have re-ceived devices of different designs, although the efficacy remains somewhat uncertain [2,3]
* National Heart & Lung Institute, Imperial College
London, Dovehouse Street, London SW3 6LY, United
Kingdom
E-mail address:p.poole-wilson@imperial.ac.uk
1551-7136/07/$ - see front matterÓ 2007 Elsevier Inc All rights reserved
Trang 3Cardiac Transplantation: Any Role Left?
Martin Cadeiras, MD, Manuel Prinz von Bayern, PhD,
Mario C Deng, MD, FACC, FESC *
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Heart transplantation was introduced as
a breakthrough therapy that dramatically
pro-longed life in individually selected patients
thought to be near death Unlike most other
ther-apeutic modalities, the survival benefit of cardiac
transplantation compared with conventional
treatment in advanced heart failure has never
been tested in a prospective randomized trial,
probably because the benefit of cardiac
transplan-tation compared with conventional therapy
usu-ally was assumed clinicusu-ally evident The early
experience at Stanford University Medical Center
between January 1968 and August 1976
demon-strated overall 1- and 2-year survival rates of
52% and 43%, respectively, and a 90% return
to functional class I New York Heart Association
(NYHA) functional status among transplant
sur-vivors, most of them returning to their preillness
activities In this initial series, 95% of the patients
selected for transplantation for whom donors did
not become available were dead 6 months after
evaluation These data suggested that cardiac
transplantation probably not only prolonged
sur-vival, but could also return carefully selected
re-cipients to active lives [1] In 1993, the 24th
Bethesda Conference on Cardiac Transplantation
recommended heart transplantation as the gold
standard therapy in selected patients who had re-fractory advanced heart failure [2] Ten years later, according to the established Registry of the International Society for Heart and Lung Transplantation, more than 3000 new transplant patients were being reported to the database each year accounting for a total of 71,040 heart transplants since it started in 1982 [3] The early observations of the Stanford group may not apply today, because major changes on the understand-ing and refinement of the therapeutic orchestra available for patients in the advanced phase of heart failure have occurred, specifically with the introduction of highly specialized heart failure units and comprehensive multidisciplinary teams; new pharmacologic compounds, including angio-tensin-converting enzyme (ACE) inhibitors, an-giotensin-receptor blockers, spironolactone and beta-blockers; novel devices, including trichamber pacemakers, defibrillators, and mechanical circu-latory support devices; and improved outcomes with high-risk cardiac surgical procedures Impor-tant improvements in the evaluation of heart transplant patients were achieved after the intro-duction of functional capacity evaluation by mea-suring oxygen consumption [4] and subsequently
a multivariate model to identify patients at highest risk of death The heart failure survival score was derived from a prospective cohort and indepen-dently validated allowing to dissect the referred population into three groups with low-, medium-,
or high-risk profile [5] Using this tool, a highly pro-vocative national cohort study suggested that heart transplantation may not confer a survival benefit during the first year posttransplantation for pa-tients having low- or medium-risk profiles [6,7] These findings were supported by subsequent re-ports using United Network for Organ Sharing
This work was supported at least in part by Grant
N HL 077096-01 from the National Institute of Health
(MPB, MCD) and by research Funds, Columbia
University, Division of Cardiology (MC)
* Corresponding author Department of Medicine,
Division of Cardiology, College of Physicians &
Sur-geons, Columbia University, 622 West 168th Street,
PH12 STEM Room 134, New York NY 10032
E-mail address:md785@columbia.edu
(M.C Deng)
1551-7136/07/$ - see front matterÓ 2007 Elsevier Inc All rights reserved